Oral MS Medications May Help You Stay on Track

Credibility

Interest

Key Takeaway

Oral MS medications may help patients stick to their treatment plan longer than injectable ones.

What They Found

In a study of 400 MS patients, those taking oral medications like dimethyl fumarate (DMF) and teriflunomide (TER) were more likely to continue their treatment for longer periods compared to those using injectable drugs. Specifically, 70.5% of patients on injectables stopped their treatment after some time, while only 42% of those on TER and 48.5% of those on DMF discontinued. The study looked at how well these treatments worked over time, focusing on whether patients experienced disease activity or progression. Even though the injectables showed higher dropout rates, the overall effectiveness in keeping disease activity low was similar among all treatment types. This suggests that how a medication is taken can be just as important as how well it works.

Who Should Care and Why

MS patients should care about this study because it highlights that choosing an oral medication might make it easier to stick with treatment, leading to better long-term health. This is similar to how some people prefer taking a daily vitamin pill rather than using a complicated method to get the same nutrients. Caregivers can also benefit from understanding these options, as they can help support their loved ones in sticking to their treatment plans. Healthcare providers can use this information to guide conversations on treatment choices, making sure patients feel comfortable with their options. Overall, knowing that oral medications may improve adherence can empower patients and caregivers to advocate for their preferred treatments.

Important Considerations

The study looked at a specific group of patients, which means the results might not apply to everyone with MS. It’s also important to note that even though oral medications showed better persistence, the effectiveness in controlling disease activity was similar across all treatments. Patients should discuss these findings with their doctors to choose the best option for their individual needs.

Categories:

Treatment Updates Living with MS Mental Wellness

Article Topics:

Dimethyl fumarateFirst-line therapiesInjectablesMultiple sclerosisNEDA-3Real-world evidenceTeriflunomideTreatment persistence

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology and therapy often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News